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Abstract
Symptoms originating from the central nervous system (CNS)
occur frequently in patients with systemic lupus erythematosus
(SLE), and CNS involvement in lupus is associated with
increased morbidity and mortality. We recently showed that
neurones and astrocytes are continuously damaged during the
course of CNS lupus. The matrix metalloproteinases (MMPs) are
a group of tissue degrading enzymes that may be involved in this
ongoing brain destruction. The aim of this study was to examine
endogenous levels of free, enzymatically active MMP-2 and
MMP-9 in cerebrospinal fluid from patients with SLE. A total of
123 patients with SLE were evaluated clinically, with magnetic
resonance imaging of brain and cerebrospinal fluid (CSF)
analyses. Levels of free MMP-2 and MMP-9 were determined in
CSF using an enzymatic activity assay. CSF samples from
another 22 cerebrally healthy individuals were used as a control.
Intrathecal MMP-9 levels were significantly increased in patients
with neuropsychiatric SLE as compared with SLE patients
without CNS involvement (P  < 0.05) and healthy control
individuals (P = 0.0012). Interestingly, significant correlations
between MMP-9 and intrathecal levels of neuronal and glial
degradation products were noted, indicating ongoing
intrathecal degeneration in the brains of lupus patients
expressing MMP-9. In addition, intrathecal levels of IL-6 and IL-
8 – two cytokines that are known to upregulate MMP-9 – both
exhibited significant correlation with MMP-9 levels in CSF (P <
0.0001), suggesting a potential MMP-9 activation pathway. Our
findings suggest that proinflammatory cytokine induced MMP-9
production leads to brain damage in patients with CNS lupus.
Keywords: cerebrospinal fluid, magnetic resonance imaging of the brain, matrix metalloproteinase-2, matrix metalloproteinase-9, neuropsychiatric 
involvement in systemic lupus erythematosus
Introduction
Central nervous system (CNS) involvement has been
reported to occur in 14–75% of all systemic lupus ery-
thematosus (SLE) patients [1-3]. However, frequency rates
vary considerably, depending on the diagnostic criteria
applied. CNS lupus can occur at any time during the
course of SLE, and its symptoms are diverse. The features
of this condition can include seizures, stroke, depression,
psychoses and disordered mentation. Neuropsychiatric
involvement in SLE (NPSLE) has been shown to predict a
high frequency of flares, and it is considered a major cause
of long-standing functional impairment as well as a cause
of mortality [4]. Over the past decade CNS lupus has been
treated with cytotoxic drugs, which improve disease out-
come [5,6].
Because of the multiple pathogenic mechanisms that
cause manifestations of CNS lupus, no single confirmatory
diagnostic test is available. Several clinical, laboratory and
radiographic test findings are reported to be abnormal in
some but not all patients with CNS lupus. Magnetic reso-
nance imaging (MRI) of brain has been shown to be valua-
ble in detecting even minor lesions caused by CNS lupus,
and these correlate with CNS manifestations in SLE [7].
Pleocytosis and elevated protein levels are found in some
but not all patients with CNS lupus [8,9]. Elevated concen-
trations of IgG in cerebrospinal fluid (CSF), IgG:albumin
ratio and IgG index, and the presence of oligoclonal bands
have all been described with varying frequencies in patients
with NPSLE [10-12]. Few studies have demonstrated ele-
vated IL-6 levels in CSF from patients with CNS lupus [13-
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17]. Some other reports have described increased levels of
IL-1 [13], IL-8 [15] and interferon-γ [18] in CSF from
patients with CNS lupus. We recently reported neuronal
damage, astrogliosis and formation of toxic metabolic prod-
ucts such as Aβ42 in patients with NPSLE [19].
One of the prototypical destructive events in the human
brain, initiated by the release of inflammatory cytokines and
ending with tissue destruction, is production of matrix met-
alloproteinases (MMPs). The MMPs are a family of
endopeptidases produced by a variety of inflammatory cells
[20]. All of the cell types that exist in the CNS are potential
sources of MMPs. In vitro, neurones, astrocytes, microglia
[21,22] and oligodendrocytes [23] express various MMP
family members, and production of MMPs by neuronal cells
can be upregulated by several inflammatory cytokines.
MMPs have a multitude of regulatory functions, including
control of influx of inflammatory mononuclear cells into the
CNS, participation in myelin destruction and disruption of
the integrity of the blood–brain barrier [24]. With respect to
MMP-9, it was recently shown that CSF levels of this
enzyme increase during bacterial meningitis and that it is
associated with brain damage [25,26]. The aim of the
present study was to measure levels of free active MMP-2
and MMP-9 in CSF of SLE patients with CNS lupus, and to
relate these data to clinical and laboratory measures of
brain parenchymal degradation. Our results suggest that
MMP-9 but not MMP-2 actively participates in brain
destruction in CNS lupus.
Methods
Participants
A total of 122 patients fulfilled four or more of the American
Rheumatism Association 1987 revised criteria for the clas-
sification of SLE [27]. The patients (106 females and 16
males, aged 17–91 years [mean age ± standard deviation
42 ± 14 years]) were being treated at the Department of
Rheumatology at Sahlgrenska University Hospital. Disease
duration varied between 0 and 49 years (mean duration 8
± 9 years). The patients were consecutively included in the
study. They underwent a thorough clinical examination by
experienced staff rheumatologist, neurologist and neu-
ropsychologist. Examination of CNS signs and symptoms
included lumbar puncture, neuropsychological tests and
MRI of the brain.
The proposed definition of CNS lupus in the American
Rheumatism Association criteria for SLE [27] appears
inadequate, given that only two elements – psychosis and
seizures – are included. As previously described [28], we
defined CNS lupus as the presence of at least two of the
following seven items in association with clinical evidence
of disease progression: recent onset psychosis, transverse
myelitis, aseptic meningitis, seizures, pathological brain
MRI, severely abnormal neuropsychiatric test findings [29]
and oligoclonal IgG bands in CSF. The pathogenesis of
antiphospholipid antibody mediated brain damage is a
thrombotic rather than inflammatory complication of SLE,
and so we decided to exclude this condition from the defi-
nition of CNS lupus. Non-SLE causes of neurological
events (e.g. cerebral infections) were also ruled out. Based
on the criteria above, patients were divided into three dis-
tinct groups: patients with CNS lupus (n = 43); patients
with SLE but without any signs of CNS involvement (n =
71); and patients with SLE complicated by antiphospholi-
pid syndrome or patients who met the CNS lupus criteria
but were ruled out because of non-SLE origin of neurolog-
ical events (n = 9). The frequencies of various CNS mani-
festations and patient treatments in the SLE patients are
summarized in Tables 1 and 2, respectively. The study was
approved by the ethical committee of the University of
Göteborg.
Control individuals
CSF from 22 healthy individuals (mean age ± standard
deviation: 38 ± 11 years; 12 females and 10 males), with-
out previous history of neurological disorder and with nor-
mal neurological status, served as control individuals. There
were no significant differences between males and females
with respect to intrathecal levels of MMP-9 (0.17 ± 0.17
pg/ml versus 0.30 ± 0.30 pg/ml; not significant) or intrath-
ecal levels of MMP-2 (388 ± 48 pg/ml versus 379 ± 48 pg/
ml; not significant).
Cerebrospinal fluid analyses
Levels of MMP-2 and MMP-9 were determined using an
activity assay system (Amersham Pharmacia Biotech,
Buckinghamshire, UK), which was constructed to measure
enzymatically active forms of MMP-2 and MMP-9. The
detection level was 190 pg/ml for MMP-2 and 125 pg/ml
for MMP-9. All values below the detection levels were con-
sidered negative. Paired serum and CSF samples were
analyzed for albumin and IgG levels using nephelometry. As
an indicator of blood–brain barrier function, the quotient of
CSF albumin × 103/serum albumin was analyzed (normal
values <6.8 [<45 years of age] and <10.2 [>45 years of
age]) [30]. The CSF/serum IgG index was used as a meas-
ure of intrathecal IgG production and calculated by using
the following formula (normal value <0.7): (CSF IgG ×
103)/([CSF albumin × 103]/serum albumin). All CSF sam-
ples were also analyzed by isoelectric focusing to permit
detection of oligoclonal IgG bands.
Magnetic resonance imaging analyses
Neuroimaging was performed to evaluate the extent and
localization of brain lesions. The neuroimaging technique
used was multiplanar MRI. The MRI examinations (Philips
Gyroscan T5-II, Einhoven, The Netherlands) were per-
formed with axial proton density and T2-weighted images of
the brain. MRI abnormalities were seen in 72% of patientsAvailable online http://arthritis-research.com/content/6/6/R551
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with CNS lupus and in 33% of SLE cases classified as cer-
ebrally healthy.
Statistical analysis
Statistical comparisons were made using the nonparamet-
ric Mann–Whitney U-test or, in case of follow-up data, the
Wilcoxon's test for paired data. Results are presented as
means ± standard error of the mean. P < 0.05 was consid-
ered statistically significant. Spearman-rank correlation
was used for calculation of correlation. The statistical anal-
yses were conducted using the Statview® (SAS, Cary, NC,
USA) program.
Results
A total of 123 patients met criteria for SLE. Forty-three
patients were found to have NPSLE (in accordance with
the criteria presented in the Methods section above), and
nine patients either were found to have phospholipid anti-
body syndrome or met the CNS lupus criteria but were
excluded because of non-SLE origin of neurological events.
The remaining 71 SLE patients were considered to be cer-
ebrally healthy.
Mild pleocytosis was seen in patients with CNS lupus (9 ×
106 ± 6 × 106 cells/l) as compared with cerebrally healthy
SLE patients (2 × 106 ± 0.5 × 106 cells/l; not significant).
As previously validated [31], we found an increased
number of oligoclonal bands in CSF from the CNS lupus
group (1.7 ± 0.4) as compared with SLE patients without
CNS involvement (0.5 ± 0.1; P < 0.05). The mean level of
CSF:serum albumin ratio was not increased in patients with
NPSLE (6.1 ± 0.7 mg/dl) as compared with cerebrally
healthy SLE patients (5.2 ± 0.3 mg/dl; not significant).
There were no significant differences in levels of serum
antibodies specific for native DNA or in complement levels
(C3 and C4) between SLE patients with and those without
CNS involvement.
Intrathecal MMP-9 levels were significantly increased in all
SLE patients as compared with cerebrally healthy control
individuals (153 ± 27 versus 0.28 ± 0.16 pg/ml; P  =
0.016). In CNS lupus patients MMP-9 levels were signifi-
cantly increased, both compared with cerebrally healthy
SLE patients (240 ± 60 versus 100 ± 20 pg/ml; P < 0.05;
Fig. 1) and compared with cerebrally healthy control indi-
viduals (240 ± 60 versus 0.28 ± 0.16 pg/ml; P = 0.0012).
Table 1
Clinical central nervous system manifestations in systemic 
lupus erythematosus patients included in the study
CNS manifestations NPSLE 
(n = 43)
No NPSLE 
(n = 71)
aPL syndrome 
(n = 9)
Acute confusional state 1 1 0
Anxiety disorder 0 5 0
Aseptic meningitis 1 0 0
Cerebrovascular disease 6 8 4
Cognitive dysfunction 9 19 1
Demyelinating syndrome 4 1 0
Headache 8 21 4
Mood disorders 5 11 1
Movement disorder 2 0 3
Myastenia gravis 0 2 0
Myelopathy 1 1 0
Polyneuropathy 0 1 0
Mononeuropathy 0 1 0
Neuropathy 0 1 0
Psychosis 7 1 0
Seizure disorders 6 2 0
Tiredness 0 8 0
Each patient may have had multiple clinical manifestations of central 
nervous system (CNS) involvement. aPL, antiphospholipid; NPSLE, 
neuropsychiatric involvement in systemic lupus erythematosus.
Table 2
Pharmacological treatment of patients with systemic lupus 
erythematosus included in the study at the time the lumbar 
puncture was performed
Treatment NPSLE 
(n = 43)
No NPSLE 
(n = 71)
aPL syndrome 
(n = 9)
Prednisolone (≤10 mg) 18 37 3
Prednisolone (>10 mg) 7 8 0
No prednisolone 18 23 5
Antimalarials 1 8 0
Azathioprine 5 10 3
Azathioprine + cyclosporin A 2 3 0
Azathioprine + antimalarials 0 0 0
Methotrexate 5 1 0
Cyclosporin A 0 6 1
Cyclophosphamide 14 10 0
Cyclophosphamide + 
cyclosporin A
30 0
Cyclophosphamide + 
antimalarials
01 0
No cytotoxic drug 11 30 4
Antihypertensive treatment 14 15 2
Low-dose aspirin 8 19 3
Warfarin 3 2 2
aPL, antiphospholipid; NPSLE, neuropsychiatric involvement in 
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On stratification of all SLE patients into two groups with
respect to the presence or absence of brain MRI pathology,
we found increased CSF MMP-9 levels in SLE patients
with MRI pathology as compared with those without (160
± 50 versus 140 ± 30 pg/ml; not significant).
There were no statistically significant differences in CSF
MMP-2 levels between NPSLE and patients without CNS
lupus (499 ± 70 versus 555 ± 70 pg/ml; not significant) or
compared with cerebrally healthy control individuals (499 ±
70 versus 384 ± 33 pg/ml; not significant; Fig. 2).
CSF levels of IL-6 (47 ± 25 pg/ml versus 15 ± 3 pg/ml; P
< 0.008) and IL-8 (91 ± 23 pg/ml versus 45 ± 6 pg/ml; P
< 0.05) were both significantly increased in CSF from
patients with CNS lupus as compared with cerebrally
healthy SLE patients, supporting our previous findings
[15,19]. Importantly, intrathecal levels of IL-6 and IL-8 sig-
nificantly correlated with those of MMP-9 (r = 0.30 [P <
0.002] and r = 0.47 [P < 0.0001], respectively; Table 3
and Fig. 3). A neuronal degeneration marker (protein tau)
and an astrocytic degeneration marker (glial fibrillary acidic
protein) were both significantly increased in CSF from
NPSLE patients as compared with CSF from SLE patients
who were clinically free from CNS involvement (311 ± 78
pg/ml versus 178 ± 16 pg/ml [P < 0.05] and 1288 ± 708
pg/ml versus 396 ± 30 pg/ml [P < 0.009]), in concordance
with previous findings [28,32]. Importantly, a significant
correlation was noted between intrathecal MMP-9 and lev-
els of tau and glial fibrillary acidic protein (P < 0.05 in both
cases; Table 3).
Discussion
We previously reported that patients with CNS lupus
express increased intrathecal levels of proinflammatory
cytokines IL-6, IL-8 and interferon-γ. Furthermore, we
recently demonstrated that inflammation in CNS during
SLE leads to neurodegeneration, which manifests as
increased levels of neuronal and astrocytic degradation
products [28,32]. However, the mechanisms responsible
for the brain damage occurring during CNS lupus have
never been clarified. It was previously demonstrated
[33,34] that proinflammatory cytokines are able to trigger
production and release of tissue-derived MMPs. It is also
established that most of the resident cells in human brain
have the capacity to produce MMP-2 and MMP-9 –
enzymes that are known to participate in brain damage (e.g.
in case of infectious meningitis) [35-37].
Figure 1
Cerebrospinal fluid expression of active matrix metalloproteinase  (MMP)-9 in patients with systemic lupus erythematosus with (NPSLE)  and without (No NPSLE) central nervous system involvement, and in  cerebrally healthy control individuals Cerebrospinal fluid expression of active matrix metalloproteinase 
(MMP)-9 in patients with systemic lupus erythematosus with (NPSLE) 
and without (No NPSLE) central nervous system involvement, and in 
cerebrally healthy control individuals.
Figure 2
Cerebrospinal fluid expression of active matrix metalloproteinase  (MMP)-2 in patients with systemic lupus erythematosus with (NPSLE)  and without (No NPSLE) central nervous system involvement, and in  cerebrally healthy control individuals Cerebrospinal fluid expression of active matrix metalloproteinase 
(MMP)-2 in patients with systemic lupus erythematosus with (NPSLE) 
and without (No NPSLE) central nervous system involvement, and in 
cerebrally healthy control individuals.
Table 3
Relationship between intrathecal expression of matrix 
metalloproteinase-9 and inflammatory cytokines, and astrocytic 
and neuronal degradation products in 119 patients with 
systemic lupus erythematosus
MMP-9
r P
MMP-2 0.40 <0.0001
IL-6 0.30 0.002
IL-8 0.47 <0.0001
Tau 0.26 0.007
GFAP 0.33 <0.04
GFAP, glial fibrillary acidic protein; MMP, matrix metalloproteinase.Available online http://arthritis-research.com/content/6/6/R551
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In the present study we found significantly higher levels of
MMP-9 in CSF from NPSLE patients than in CSF from SLE
patients without CNS lupus and healthy control individuals.
This finding may be of clinical significance because of cor-
relation between MMP-9 and levels of neuronal/astrocytic
degradation products in CSF, reflecting the potential of
MMP-9 to damage brain parenchyma. Findings of a rela-
tionship between MMP-9 and brain damage in SLE are new
and should be scrutinized critically. We believe that effort
should be invested in analyzing free (i.e. non-tissue inhibitor
of metalloproteinase bound) and metabolically active
enzyme to ascertain the validity of our conclusions. The
method used in the present study fulfils both of these
requirements.
MMP-9 plays an essential role in the breakdown of extracel-
lular matrix molecules at the blood–brain barrier. This,
together with locally elevated levels of the chemokine IL-8,
greatly facilitates the transmigration of activated inflamma-
tory cells across the endothelium. Indeed, a significant cor-
relation was observed between the intrathecal levels of
MMP-9 and IL-8.
A broad range of cytokines that are expressed in viral men-
ingitis are able to regulate the production of MMPs and tis-
sue inhibitors of metalloproteinase [38,39]. IL-1α and IL-
1β, as well as IL-6, induce or upregulate the transcription of
MMP genes [40]. This, along with increased IL-6 levels in
CSF of patients with CNS lupus, may provide an explana-
tion for the local synthesis of MMP-9.
CSF levels of enzymatically active MMP-2 were not
increased in NPSLE patients as compared with SLE
patients without CNS involvement or compared with cere-
brally healthy control individuals. This finding is consistent
with a previous study of viral meningitis, in which increased
expression of MMP-9 but constitutive expression of MMP-
2 was found [37]. The reason for this discrepancy, seen in
the present study as well as in the previous one, might be
differential regulation of gene promotors for MMP-9 and
MMP-2. Indeed, whereas the promotor regions of MMP-9,
which is regulated by cytokines, harbor a nuclear factor-κB
responsive element, those of MMP-2 lack a TATA box and
contain two SP-1 sites, both characteristic of house keep-
ing genes [40,41].
Conclusion
Our present and previous findings indicate that the follow-
ing chain of events takes place during NPSLE: intrathecal
release of inflammatory cytokines, leading to synthesis and
release of MMP-9, potentially culminating in insult to brain
parenchyma, resulting in release of neuronal and astrocytic
degradation products and culminating in MRI verifiable
lesions and clinical states of brain deficiency. Interestingly,
a recent study [42] indicated that IgG dose-dependently
downregulates secretion of MMP-9 by macrophages, sug-
gesting a possible early therapeutic manipulation in
NPSLE.
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